Market Context — Why This Technology, Why Now

The accelerating pace of personalized medicine and precision diagnostics is driving urgent demand for more efficient and accurate tools to analyze gene expression and epigenetic modifications. Simultaneously, the biopharmaceutical industry is under pressure to shorten drug development cycles and reduce R&D costs, with an estimated $250K/year savings per facility possible. This technology directly supports these trends by simplifying complex chromatin analysis, enabling faster biomarker discovery and therapeutic development across global markets.

Key Competitive Advantages
01

Reduces detection time by ~20% for high-sensitivity, simplified chromatin analysis

02

Enables sequence-independent nucleic acid binding, expanding applicability across all species and genomic regions

03

Establishes strong market advantage, validated by overcoming 8 prior art references and two office actions

Market Opportunity
🔬 Drug Discovery Research
$13.5B globally (AI est.)
Abnormalities in gene expression regulation cause many diseases, making chromatin structure analysis essential for novel drug target identification and drug screening. Improved detection efficiency directly shortens development timelines and reduces costs.
Pharmaceutical R&D divisions Biotech drug developers Contract research organizations (CROs)
🧪 Diagnostic Development
$10B globally (AI est.)
The importance of gene expression profiling as a disease biomarker is growing. This technology could be applied to develop high-sensitivity diagnostic kits, particularly contributing to early diagnosis and personalized medicine.
Medical device manufacturers In vitro diagnostics (IVD) companies Clinical pathology labs
🧬 Basic Life Science Research
$10B globally (AI est.)
In gene expression regulation and epigenetics research, chromatin structure analysis is a fundamental yet complex process. This simple, high-sensitivity technology could reduce researchers' workload and accelerate new discoveries.
Academic research institutions Government research labs Biotechnology tool providers
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects a nucleic acid binding protein comprising a DNA binding domain with three or more TAL-repeats, characterized by sequence-independent nucleic acid binding. The patent's 15 broad claims, having overcome 8 prior art references and two office actions, indicate robust validity and low invalidation risk, securing a strong scope of protection for its structure and function.

Competitive White Space

This patent primarily covers the protein's structure and detection function. White space exists in developing specific delivery systems for in vivo applications, integrating the protein into advanced microfluidic platforms, or exploring its use in gene modulation therapies beyond mere detection.

Economic Impact
~$250K/year estimated R&D cost reduction per facility (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

By improving R&D process efficiency, this technology could significantly reduce chromatin structure detection time and costs. For example, a ~20% reduction in detection task time could save ~$65K (AI est.) annually from 5 researchers' salaries (at ~$65K/researcher/year, AI est.). Furthermore, a ~30% reduction in annual expensive sequence-specific probe purchases (from ~$650K annual reagent costs, AI est.) could save ~$200K (AI est.), totaling an estimated annual cost reduction of ~$265K (AI est.).

Speed to Market
6× faster than in-house development
Basic research for this nucleic acid binding protein technology has been completed by a national R&D agency, with its fundamental characteristics already established. For a licensee, this could shorten development time by approximately 2.5 years compared to starting R&D from scratch. The willingness to license suggests a smooth technology transfer process, enabling rapid product commercialization and service deployment. Leveraging existing protein expression and purification facilities could minimize additional capital investment, significantly accelerating time-to-market.
Competitive Positioning

X: Detection Efficiency & Simplicity
Y: Applicability & Versatility

Business Models & Applications
🧪 Sale as Research Reagent
Selling the nucleic acid binding protein as a research reagent to academic institutions and pharmaceutical companies could reach a broad customer base and establish a stable revenue stream.
💊 Application in Diagnostic Kits & Licensing
Applying this technology in diagnostic kits for early disease detection and biomarker identification, then licensing to pharma and medical device manufacturers, could capture a significant market share in healthcare.
🤝 New Technology Creation through Collaborative R&D
Pursuing collaborative R&D with companies and research institutions focused on specific disease mechanisms or novel therapies could create new technological value and revenue streams.
Adjacent Application Opportunities
🧬 Genome Editing
Genome Editing Efficiency Tool
This technology could be applied to evaluate off-target effects and editing efficiency of genome editing tools (e.g., CRISPR/Cas9) by leveraging its chromatin open structure detection capabilities. This offers a more precise and simplified assessment, contributing to improved R&D accuracy and real-time cellular state monitoring.
🦠 Environmental Biotechnology
Environmental DNA Detection Probe
This technology could be repurposed as a sequence-independent probe for detecting microbial or species DNA in environmental samples. This would provide rapid and broad DNA detection solutions for environmental biotech applications, including water quality testing, soil contamination monitoring, and ecosystem surveys.
🍎 Food Inspection
GMO & Allergen Detection in Food
This technology could be applied to develop simple, high-sensitivity test kits for detecting DNA from genetically modified organisms (GMOs) or allergens in food products. Its ability to detect DNA even when specific sequence information is unknown makes it a rapid and reliable tool for food safety assessment and quality control.
Integration Roadmap — Estimated 12-Month Deployment
Phase 1: Technology Evaluation & Prototype Design
Duration: 3 months
Optimize expression and purification conditions for the nucleic acid binding protein, assessing compatibility with existing licensee systems. Design an initial prototype and confirm basic binding characteristics.
Phase 2: System Integration & Functional Validation
Duration: 6 months
Integrate the designed prototype into the licensee's existing detection systems and workflows. Conduct detailed functional validation using real samples, evaluating performance metrics such as detection sensitivity, specificity, and reproducibility.
Phase 3: Field Deployment & Optimization
Duration: 3 months
Deploy the validated system into actual research or diagnostic processes. Optimize operability and data analysis based on field feedback, establishing a stable operational framework.
Technical Feasibility
The nucleic acid binding protein's structural design, featuring a DNA binding domain with three or more TAL-repeats, is estimated to be synthesizable using existing protein expression and purification technologies. This suggests licensees could integrate the technology without significant new capital investment, maximizing use of existing bioproduction facilities and research infrastructure. Furthermore, its sequence-independent binding eliminates the need for complex probe redesign for each target, indicating low technical hurdles.
Success Scenario
Implementing this technology could improve the screening process for drug candidates in pharmaceutical research by approximately 20%. This could increase the number of compounds screened annually by 1.2 times, potentially shortening new drug development timelines and improving success rates. In diagnostic development, it is estimated to enable high-sensitivity detection of trace biomarkers previously difficult to detect, enhancing early disease detection and personalized treatment accuracy.
Patent Record
APPLICATION NO.
特願2021-513700
REGISTRATION NO.
7356739
FILING DATE
2020/04/09
GRANT DATE
2023/09/27
EXPIRATION DATE
2040/04/09
PATENT HOLDER
国立研究開発法人科学技術振興機構
Examination History
2021年07月20日
出願審査請求書
2022年06月28日
拒絶理由通知書
2022年10月14日
意見書
2023年02月07日
拒絶理由通知書
2023年06月08日
手続補正書（自発・内容）
2023年06月08日
意見書
2023年09月05日
特許査定